- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00000721
An Escalating Dose Tolerance Trial of BG8962 (rCD4) in Patients Who Are HIV Antibody Positive
Study Overview
Detailed Description
Recombinant soluble CD4 protein (rCD4) is a drug that has been produced by genetic engineering techniques. In laboratory studies, rCD4 binds to HIV and reduces its ability to enter the cell, thus inhibiting its reproduction. Before rCD4 can be tested for therapeutic effectiveness in HIV-infected patients, it is necessary to determine the maximum dose that can be tolerated by humans. AMENDED: To date, Biogen's original sequence recombinant soluble CD4 and Biogen's natural sequence recombinant soluble CD4 have both been referred to as recombinant soluble CD4 (rsCD4). In order to distinguish between these two products, a change in nomenclature has been made. In this protocol, whenever the original sequence CD4 molecule is referred to, it is called recombinant soluble T4 (rsT4). Whenever the natural sequence molecule (currently under study in this protocol) is referred to, it is called BG8962 or rCD4. Whenever the drug is discussed generically, it is referred to as rsCD4.
The initial dose level is the highest dose previously established with other patients in this trial to be safe when administered intramuscularly (IM). Dose escalation is by semilogarithmic steps. A shift from IM injection to continuous subcutaneous infusion (CSCI) is necessitated by the volume of drug which is administered as part of the escalation dose. Three groups of eight patients each are treated as follows. The first group of 8 patients receives BG8962 daily and consists of two cohorts of four patients each. One cohort receives BG8962 as an IM injection. The second cohort receives BG8962 as a continuous 24 hour infusion. All patients in this group are treated for 12 weeks. The second dosing group of 8 patients receive daily BG8962 by CSCI for 12 weeks. The third group of 8 patients receive BG8962 by CSCI for 6 weeks. Every two weeks during the study the following tests and evaluations are done: Blood chemistry, hematology, urinalysis with microscopic exam, and T-cells and T-cell subsets.
Study Type
Enrollment
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Palo Alto, California, United States, 943055107
- Stanford CRS
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
Concurrent Medication:
Allowed:
- Nystatin or clotrimazole for suppression of oral thrush.
- Aerosolized pentamidine for Pneumocystis prophylaxis in Group A patients.
- Trimethoprim / sulfamethoxazole for Pneumocystis prophylaxis in patients who are hematologically stable on trimethoprim / sulfamethoxazole.
Patients must have:
- Group A: AIDS and symptoms defined in disease status.
- Group B: AIDS related complex (ARC) and symptoms defined in disease status.
Exclusion Criteria
Co-existing Condition:
Patients with the following disease or conditions are excluded:
- Malignancies other than Kaposi's sarcoma.
- AIDS dementia.
- Opportunistic infections requiring ongoing therapy except oral thrush suppression with nystatin or clotrimazole or Pneumocystis prophylaxis in Group A patients.
- Significant organ system dysfunction including:
- Granulocytopenia with a granulocyte count < 1000 cells/mm3.
- Thrombocytopenia - < 75000 platelets/mm3.
- Anemia with a hemoglobin < 9.5 g/dl.
- Renal dysfunction - creatinine > 2 mg/dl.
- Hepatic dysfunction with enzymes or bilirubin > 3 x upper limit of normal.
Patients with the following are excluded:
- Preexisting antibodies to rCD4.
- Malignancies other than Kaposi's sarcoma.
- AIDS-dementia complex.
- Opportunistic infections requiring ongoing therapy.
- Significant organ system dysfunction.
- Inability to sign voluntarily the consent form.
Prior Medication:
Excluded:
- Recombinant soluble CD4 protein (rCD4).
- Excluded within 30 days of study entry:
- Immunomodulatory therapy or agent with anti-HIV activity.
- Chemotherapy.
Prior Treatment:
Excluded within 30 days of study entry:
- Radiotherapy.
Active illicit drug use or alcohol abuse at time of entry.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Masking: None (Open Label)
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Schooley RT
Study record dates
Study Major Dates
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ACTG 066
- 11040 (DAIDS ES Registry Number)
- 066 Extension
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on CD4 Antigens
-
Genentech, Inc.CompletedHIV InfectionsUnited States
-
Genentech, Inc.Completed
-
National Institute of Allergy and Infectious Diseases...Genentech, Inc.Completed
-
National Institute of Allergy and Infectious Diseases...BiogenTerminatedHIV InfectionsUnited States
-
University of Erlangen-Nürnberg Medical SchoolActive, not recruitingConfocal Laser Endomicroscopy to Determine Influence of Food Antigens on Mucosal Integrity (RDS_CLE)Irritable Bowel Syndrome | Food Sensitivity | Healthy ControlsGermany
-
Marcin StraburzynskiCompletedUpper Respiratory Tract InfectionsPoland
-
iCell Gene TherapeuticsPeking University Shenzhen Hospital; iCAR Bio Therapeutics Ltd.RecruitingRefractory T-Cell Lymphoma | T Cell Lymphoma in RelapseChina
-
Singh, Ranjan Kumar, M.D.CompletedHIV Infections | Tuberculosis | Cryptococcosis | Leishmaniasis | Candidiasis, Esophageal | ToxoplasmosisIndia
-
Genentech, Inc.CompletedHIV Infections | Immune Thrombocytopenic Purpura ( ITP )United States